ARTICLE | Clinical News
Apan beta amyloid 5-amino acid inhibitor: Started Phase I testing
January 2, 2001 8:00 AM UTC
Praecis Pharmaceuticals Inc. (PRCS), Cambridge, Mass. Product: Apan beta amyloid 5-amino acid inhibitor Business: Neurological Therapeutic category: Neuroprotectant Target: Beta amyloid Description:...